EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice

Vaishali Sanchorawala iD, Ashutosh D Wechalekar, Kihyun Kim, Stefan O Schönland, Heather J Landau, Fiona Kwok, Kenshi Suzuki, Angela Dispenzieri iD, Giampaolo Merlini, Raymond L Comenzo, Dasha Cherepanov, Vanessa C Hayden und 4 weitere

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26866 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Vaishali Sanchorawala und 15 weiteren Autor:innen. Beteiligte Einrichtung: Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Amyloidosis, Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Physicians. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, AHRQ HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patient‐reported outcomes in AL amyloidosis have not been well‐studied. We analyzed health‐related quality of life (HRQOL) and AL amyloidosis symptoms data from the phase 3 TOURMALINE‐AL1 trial (NCT01659658) (ixazomib‐dexamethasone, n = 85; physician's choice of chemotherapy [PC], n = 83). HRQOL and symptom burden were measured with the SF‐36v2, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity subscale (FACT/GOG‐Ntx), and an amyloidosis symptom questionnaire (ASQ). Score changes during treatment were analyzed descriptively and using repeated‐measures linear mixed models; analyses were not adjusted for multiplicity. Least‐squares (LS) mean changes from baseline were significantly higher (better HRQOL) for ixazomib‐dexamethasone at several cycles for SF‐36v2 Role Physical and Vitality subscales ( p < .05); no subscales demonstrated significant differences favoring PC. For FACT/GOG‐Ntx, small but significant differences in LS mean changes favored ixazomib‐dexamethasone over PC at multiple cycles for seven items and both summary scores; significant differences favored PC for one item (trouble hearing) at multiple cycles. ASQ total score trended downward (lower burden) in both arms; significant LS mean differences favored ixazomib‐dexamethasone over PC at some cycles ( p < .05). Patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone experienced HRQOL and symptoms that were similar to or trended better than patients treated with PC despite longer duration of therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmyloidosisImmunoglobulin Light-chain AmyloidosisMultiple MyelomaPhysiciansFemaleHumansAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneQuality of LifeBoron CompoundsGlycine

Substanzen

DexamethasoneixazomibBoron CompoundsGlycine

Autor:innen und Institutionen

  • Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
  • National Amyloidosis Centre, Royal Free London NHS Foundation Trust, University College London, London, UK.
  • Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Medicine V (Hematology, Oncology and Rheumatology), Amyloidosis Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.
  • Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Clinical Haematology, Westmead Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Vaishali Sanchorawala, Angela Dispenzieri

Förderung

  • NIA NIH HHS
  • AHRQ HHS

Zitieren

APA

Sanchorawala, V., Wechalekar, A. D., Kim, K., Schönland, S. O., Landau, H. J., Kwok, F., Suzuki, K., Dispenzieri, A., Merlini, G., Comenzo, R. L., Cherepanov, D., Hayden, V. C., Kumar, A., Labotka, R., Faller, D. V., & Kastritis, E. (2023). Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice. American Journal of Hematology. https://doi.org/10.1002/ajh.26866

Vancouver

Sanchorawala V, Wechalekar AD, Kim K, Schönland SO, Landau HJ, Kwok F, et al. Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice. American Journal of Hematology. 2023. doi:10.1002/ajh.26866

BibTeX
@article{Sanchorawala2023,
  author = {Sanchorawala, Vaishali and Wechalekar, Ashutosh D and Kim, Kihyun and Schönland, Stefan O and Landau, Heather J and Kwok, Fiona and Suzuki, Kenshi and Dispenzieri, Angela and Merlini, Giampaolo and Comenzo, Raymond L and Cherepanov, Dasha and Hayden, Vanessa C and Kumar, Arun and Labotka, Richard and Faller, Douglas V and Kastritis, Efstathios},
  title = {Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26866}
}
Kostenlos starten →